Clinical Trial Update: A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay

View source ↗

Summary

Completed clinical trial evaluating the clinical outcomes associated with the NanoString Prosigna gene signature assay in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: NanoString Technologies, Inc. | Conditions: Breast Cancer | Status: COMPLETED